Drugs / 23-valent pneumococcal vaccine
23-valent pneumococcal vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00741039 | Aug 2008 → Aug 2012 | breast cancer, lung cancer, prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT02079701 | Oct 2000 → Jun 2003 | pneumonia | Naval Health Research Center | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00279734 Background | Aug 2004 → Jan 2005 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 23-valent pneumococcal vaccine | “the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly)” NCT00741039 ↗ |
| Known as | 23-valent polysaccharide pneumococcal vaccine | “This study evaluated the effectiveness of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in reducing pneumonia in healthy military trainees.” PMID 25579777 ↗ Jan 2015 |
| Known as | Pneumovax | “PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly)” NCT00741039 ↗ |
| Known as | PPV23 | “This study evaluated the effectiveness of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in reducing pneumonia in healthy military trainees.” PMID 25579777 ↗ Jan 2015 |
| Known as | PPV23 vaccine | “PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly)” NCT00741039 ↗ |
| Modality | Vaccine | “the intramuscular 23-valent pneumococcal vaccine” PMID 17425783 ↗ 2007 |
| Route | Intramuscular | “the intramuscular 23-valent pneumococcal vaccine” PMID 17425783 ↗ 2007 |